(NYSE: ANVS) (Annovis or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity) in a mouse model of Alzheimers disease
Current Alzheimer research
This is just one part of the digestive system, which operates like a fine-tuned machine with many smaller processes
Its More Than Weight Loss More energy
"Reaction mechanism of glutathione synthetase from Arabidopsis thaliana: site-directed mutagenesis of active site residues"
According to Kim, Nature Communications , MOTS-c administration improved glucose tolerance and physical capacity in mice, confirming its role in regulating energy homeostasis